News Release: Precision BioLogic Launches Product to Improve Inhibitor Testing for People with Hemophilia A

HALIFAX, February 11, 2019—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities last month.
The presence of factor VIII (FVIII) inhibitors reduces therapy effectiveness and is one of the most complex and costly complications for people with hemophilia A. Because of this, it is important for clinical laboratories to have a testing system that can accurately and precisely quantify FVIII inhibitors in patient samples.
Follow link above to read full release

See full news release here

Province Announces Innovation Equity Tax Credit

Read original announcement here
Nova Scotia startup companies and small and medium-sized businesses will benefit from more investment, thanks to a new Innovation Equity Tax Credit launched today by Finance and Treasury Board Minister Karen Casey.
The new tax credit applies to investments up to $250,000 in eligible businesses, which is $200,000 more than the current Equity Tax Credit. Nova Scotian investors will receive a tax incentive of 35 per cent, or 45 per cent in priority sectors of oceans technology and life sciences.

“This new tax credit encourages Nova Scotians to invest in our home-grown entrepreneurs and local companies so they can drive growth, be more competitive and succeed,” said Ms. Casey. “It will add to our ongoing efforts to improve the business climate in Nova Scotia for innovation-driven entrepreneurship by doing things differently to support economic growth.”

The revised regulations outline that Nova Scotia businesses less than 10 years old may qualify for funding. Investors often bring expertise, advice, mentoring and networks to the businesses they have invested in.
The province is also exploring options to expand the tax credit through legislation this spring. Those options include making corporations and qualified venture capital funds eligible for the credit.
The new tax credit focuses on innovation-driven entrepreneurship and narrows business eligibility to priority areas. The current equity tax credit, established in 1994, will be phased out as part of the 2019-20 Budget, to enable time for businesses to adjust.
The new tax credit is effective immediately. To view the regulations visit, https://novascotia.ca/just/regulations/rxaa-l.htm#inctax .

FOR BROADCAST USE:

Nova Scotia startups will benefit from a new Innovation Equity Tax Credit that encourages more local investment.
The new tax credit focuses on innovation-driven entrepreneurship and narrows business eligibility to priority areas, including ocean technology and life sciences.
Finance and Treasury Board Minister Karen Casey says new investments in local companies will help to create a stronger Nova Scotia.
This will help build on the flourishing startup community we have in the province.
The new tax credit is effective immediately.

Media Contact:

Gary Andrea
902-456-6196 Email:

ENTREVESTOR: Adaptiiv Lands Clients in 7 Countries

Read the original article here.  Halifax-based Adaptiiv has announced major new clients in Hong Kong and the U.S. as the young medical technology company expands its customer base to seven countries. The company – which uses 3D printing technology to improve radiation therapy in cancer treatment – said Monday it had signed a deal to sell its product to University of Hong Kong and work with the institution as a research partner. That announcement came days after Adaptiiv announced its 3D Bolus technology would be used by the U.S. Military at the Walter Reed National Military Medical Center.  Dubbed “The Nation’s Medical Center,” the Reed is the United States’ largest and most renowned joint military medical facility, providing services in over 100 clinics and specialties. “We have accomplished a lot in a short period of time and I am very proud of the team but I feel we are just getting started,” said CEO Peter Hickey in an email Sunday night. Just two years old, Adaptiiv has quickly found customers for its 3D Bolus product, which revolutionizes the use of a bolus in radiation therapy. A bolus is a piece of plastic placed over the cancerous area, assuming the tumours are close to or in the skin. The radiation hits the bolus, builds up and then is transferred into the tumour. There can be no air pockets between the bolus and the skin, which complicates matters given that every body is unique. Hospitals using the Adaptiiv product buy a system that includes 3D printers with special filaments, so boluses customized to each patient can be printed within seconds. They can be reused as the patient receives repeated radiation dosages. Or, if the patient’s body shape changes over the course of multiple treatments, the medical staff can print off another bolus quickly. In June, the company announced it had received 510(k) clearance from the U.S. Food and Drug Administration, allowing the product to be sold in the U.S. That opened the flood gates to more sales, and to announcements of new partnerships and projects. The company’s software is now used in the U.S., Canada, Australia, Israel, Ireland, England and now Hong Kong. The university in Hong Kong will use 3D Bolus in radiation therapy and its Department of Clinical Oncology will work with Adaptiiv to develop new applications. Meanwhile, Adaptiiv last week also released a new product called AccuCALC, which helps cancer centers to assess the business case for offering the 3D Bolus product. AccuCALC was developed by Churchill Consulting, which provides consulting and integrated system solutions to radiation therapy departments. Rules for billing insurers vary from state to state in the U.S., and facilities that offer radiation therapy can use AccuCALC to assess how and when they can charge for using the 3D Bolus product. “We have seen significant demand from our clients for information pertaining to 3D Bolus,” said Jordan Johnson, Churchill’s Director of Compliance. “Yet. as is common with many leading-edge technologies, our clients are unsure of whether they can bill for a new technology or its potential return on investment.  AccuCALC addresses that problem.”]]>

DNA Insights Change the Injury Prevention and Rehab Industry

Athletigen teams up with CrossFit leader MobilityWOD   HALIFAX – September 17, 2018 – Athletigen Technologies, Inc. has announced the launch of its Optimum Movement and Recovery report, a DNA product that was created in partnership with Dr. Kelly Starrett and his company MobilityWOD.   The report uses 23andMe, AncestryDNA, or Athletigen DNA data, for more than 70 genetic markers to deliver 25 fundamental insights into injury risk, exercise recovery, and sleep hygiene. Customers who have already had their DNA sequenced can now use the Optimum Movement and Recovery report to gain additional knowledge about their bodies. Alternatively, if customers need a DNA kit to start their genetic journey, they can purchase one directly from Athletigen.   “It’s exciting to see people use their DNA to explore the depths of their unique human technology. Working together with Dr. Kelly and Juliet Starrett to deliver a solution that helps people make informed decisions for optimal performance and informed living has been pure joy,” says Athletigen CEO Dr. Jeremy Koenig. “It is an honour to work side by side with people who are experts in their craft and who are driven to help humans perform, feel, and live better. We want to continue to help people make decisions based on their individual bodies. This kind of interdisciplinary collaboration is essential to make this a reality for all humans.”   The Optimum Movement and Recovery report, while non-diagnostic, helps customers understand the impact of DNA on traits such as tendon and ligament injury risk, post-exercise soreness and inflammation, and sleep quality. Understanding our DNA foundation can be empowering, giving every person the ability to take charge of their health. Every person’s DNA is 99.5% the same. By understanding the 0.5% that makes each person unique, as well as the environmental factors that combine with DNA to influence athletic performance and recovery, people can make more informed lifestyle decisions daily.   MobilityWOD was founded in 2005 by Dr. Kelly Starrett and Juliet Starrett with the goal of becoming the ultimate guide to eliminating pain, preventing injury and maximizing athletic performance. MobilityWOD has grown into a leader in the CrossFit industry and has worked with high-profile clients such as the New Zealand All Blacks, UFC fighter Georges St. Pierre, actor Jason Statham, and author Tim Ferriss.   “Genetics and understanding the implication of modern genetics on my person is here to stay. It’s going to be part of the conversation,” said MobilityWOD founder Kelly Starrett. “The problem is that trying to sort through and make sense of this incredible technology is difficult, at best. So we have partnered with our friends at Athletigen to take your DNA data and translate it into actionable steps and real behaviors that can improve your life.”   Athletigen is funded by private equity investors, the Government of Canada through repayable loans from the Atlantic Canada Opportunities Agency, and the province of Nova Scotia through Nova Scotia Business Inc.   —- 30 —- Click here for a sample version of the Optimum Movement and Recovery DNA report.   Media Contact Brandon DuBreuil brandon.dubreuil@athletigen.com   About Athletigen Athletigen is a company founded on the same performance principles that are used to help the most elite athletes in the world achieve greatness. We are driven to empower all people to understand their DNA and reach their full potential. Our mission is to help people connect their DNA data to products and services that are specific to their personal needs and are aligned with a healthful life. We achieve this through adhering to the highest scientific standards, a commitment to education, and strategic alignment with partners who embrace our passion for performance. We believe that everyone is Made for More™.   About Athletigen’s Optimum Movement and Recovery Report The new Optimum Movement and Recovery DNA report from Athletigen and MobilityWOD unlocks the power of raw DNA data files provided to every 23andMe and AncestryDNA customer with over 25 insights into injury risk, exercise recovery, and sleep hygiene. These traits include:

  • Tendon and ligament injury risk
  • Hamstring injury risk
  • Shoulder dislocation
  • Fracture risk and bone mineral density
  • Age-related strength loss
  • Post-exercise soreness and inflammation
  • Post-exercise recovery time
  • Soft tissue recovery
  • Sleep quality
  About Dr. Jeremy Koenig Dr. Jeremy Koenig, Athletigen CEO and Founder, has a background in commercializing genetic information into practical applications. Dr. Koenig was a varsity track-and-field athlete during the completion of his Ph.D. in Biochemistry and Molecular Biology at Dalhousie University in Halifax, Nova Scotia, Canada. Following graduate school, Dr. Koenig pursued postdoctoral training in human microbiome and genetics research at Cornell University. He was a Professor of Nutrigenomics, before moving to the biomedical industry to work on developing and commercializing a genetics-based fertility test. He founded Athletigen in 2014 to accelerate scientific discovery through the delivery and application of DNA to every human.   Athletigen Technologies Inc., 211 Horseshoe Lake Drive, Halifax, Nova Scotia]]>

IMV Inc. Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia

See original article here

DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in Dartmouth, Nova Scotia. Frederic Ors, IMV’s Chief Executive Officer, and Andrew Sheldon, IMV’s Chairman of the Board, opened today’s event with remarks about the company’s milestones and successes. Other speakers included federal MP Darren Fisher, the Honourable Randy Delorey, Minister of Health and Wellness, and Dartmouth Centre Councillor Sam Austin. Emilie Chiasson, the Atlantic Regional Director of Ovarian Cancer Canada, served as the event’s Master of Ceremonies.

IMV Grand Opening
Councillor Sam Austin, Minister Randy Delorey, MP Darren Fisher, IMV Chairman Andrew Sheldon, IMV CEO Frederic Ors, IMV CMO Gabriela Rosu, and IMV CFO Pierre Labbé participated in today’s grand opening event for IMV’s new facilities in Dartmouth.
“The opening of our new facility marks another successful stage of growth for IMV, which will enable us to accelerate and expand on our ambitious research and clinical development programs,” said Frederic Ors.  “We are focused on attracting and retaining the best employees for a clear purpose: to develop breakthrough immunotherapies for individuals living with serious medical conditions such as ovarian and lymphoma cancers.  We look forward to continuing our growth with the strong support of the local community in Nova Scotia.” The Company moved from its offices and laboratories located in the Innovacorp Enterprise Centre on Summer Street, Halifax, to the Bluefrog Business Campus in Dartmouth to accommodate the growing business. The new space features upgraded facilities and equipment as well as increased laboratory size and capacity. IMV has now nearly tripled its space to allow for expanding business and operations in the coming years. “IMV is providing high-quality jobs for our region’s educated workforce, helping to attract and retain talent. It is also drawing international attention to the work that is being done within the life sciences community in Nova Scotia,” says Darren Fisher, Member of Parliament for Dartmouth-Cole Harbour, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for Atlantic Canada Opportunities Agency (ACOA). “This kind of recognition, combined with business successes such as becoming a publicly traded company on the TSX and Nasdaq, has helped to bring significant investment to the area. This is why the Government of Canada, through the ACOA, has been a proud supporter since the get-go, assisting with funding for research and development, patent protection, and bringing the Company’s product candidates to market.” About IMV IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: surviving. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com. IMV Forward-Looking Statements This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. Contacts for IMV: MEDIA  Mike Beyer, Sam Brown Inc. T: (312) 961-2502 E: mikebeyer@sambrown.com INVESTOR RELATIONS Pierre Labbé, Chief Financial Officer T: (902) 492-1819 E: info@imv-inc.com Patti Bank, Managing Director, Westwicke Partners O: (415) 513-1284 T: (415) 515-4572 E: patti.bank@westwicke.com A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1b59b9b0-072e-4428-a03f-42605483f01b]]>